Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency

被引:2
作者
Peltier, Skye [1 ]
Kellum, Angela [2 ]
Brewer, Janet [3 ]
Duncan, Alexander [4 ]
Cooper, David L. [5 ]
Saad, Hossam [5 ]
机构
[1] Univ Minnesota, Med Ctr Fairview, Ctr Bleeding & Clotting Disorders, Minneapolis, MN 55455 USA
[2] Tulane Univ, Louisiana Ctr Bleeding & Clotting Disorders, New Orleans, LA 70118 USA
[3] Comprehens Hlth Educ Serv, Hanson, MA USA
[4] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[5] Novo Nordisk Inc, Plainsboro, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2020年 / 11卷
关键词
bleeding disorder; psychosocial impact; recombinant activated factor VII; survey; RARE; PROPHYLAXIS; DISORDERS; SEVERITY;
D O I
10.2147/JBM.S259909
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Congenital factor VII (FVII) deficiency is a rare bleeding disorder of variable phenotype with predominantly mucocutaneous bleeding. The aim of this study was to identify the burden of FVII deficiency on patients and caregivers through a better understanding of the management and psychosocial impact of this disease. Materials and Methods: A rare disease specialty recruiter from Comprehensive Health Education Services recruited participants for this online survey, which was conducted from January 31 to March 12, 2019. A moderator-assisted questionnaire was used to collect data on demographics, diagnosis, treatment, and psychosocial impact. Results: Of the 45 respondents (25 patients and 20 caregivers), the majority were female (56%). Respondents reported a wide variety of initial bleeding symptoms, including bruising (58%), epistaxis (56%), and menorrhagia (36% of females). Because symptoms varied between individuals and were not always severe, diagnosis was often delayed. Mean time to obtain a diagnosis was 6.5 years and mean age at first diagnosis was 12.9 years. One-quarter (24%) of the respondents reported more than 100 bleeds of any severity over the previous year. When treating bleeds, 44% of patients reported using antifibrinolytics, and 42% reported using recombinant activated factor VII. Almost 31% of respondents reported missing schooldays as children, and 16% reported losing or resigning from a job in adulthood as a direct result of their disease. Notably, 29% of caregivers and 10% of their partners had also experienced issues with employment. Forty percent of respondents reported not participating in contact sports during childhood, and 22% continued to avoid contact sports in adulthood. Conclusion: Overall, FVII deficiency has a substantial psychosocial impact, but most patients are satisfied with their disease management and are optimistic about their future. Patients desire additional educational, social, and financial support.
引用
收藏
页码:297 / 303
页数:7
相关论文
共 21 条
[1]   Inherited Bleeding Disorders in the Obstetric Patient [J].
Bannow, Bethany Samuelson ;
Konkle, Barbara A. .
TRANSFUSION MEDICINE REVIEWS, 2018, 32 (04) :237-243
[2]   Inhibitors to factor VII in congenital factor VII deficiency [J].
Batorova, A. ;
Mariani, G. ;
Kavakli, K. ;
de Saez, A. R. ;
Caliskan, U. ;
Karimi, M. ;
Pinotti, M. ;
Napolitano, M. ;
Dolce, A. ;
Sorensen, B. ;
Ingerslev, J. .
HAEMOPHILIA, 2014, 20 (02) :E188-E191
[3]   Rare coagulation disorders: fibrinogen, factor VII and factor XIII [J].
de Moerloose, P. ;
Schved, J. -F. ;
Nugent, D. .
HAEMOPHILIA, 2016, 22 :61-65
[4]   Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project [J].
Elbatarny, M. ;
Mollah, S. ;
Grabell, J. ;
Bae, S. ;
Deforest, M. ;
Tuttle, A. ;
Hopman, W. ;
Clark, D. S. ;
Mauer, A. C. ;
Bowman, M. ;
Riddel, J. ;
Christopherson, P. A. ;
Montgomery, R. R. ;
Rand, M. L. ;
Coller, B. ;
James, P. D. .
HAEMOPHILIA, 2014, 20 (06) :831-835
[5]   Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [J].
Franchini, Massimo ;
Marano, Giuseppe ;
Mengoli, Carlo ;
Piccinini, Vanessa ;
Pupella, Simonetta ;
Vaglio, Stefania ;
Liumbruno, Giancarlo Maria .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2018, 44 (06) :595-603
[6]   Recombinant activated factor VII: 30 years of research and innovation [J].
Hedner, Ulla .
BLOOD REVIEWS, 2015, 29 :S4-S8
[7]  
Holve Steven, 2001, Pediatric Research, V49, p203A
[8]  
Huth-Kühne A, 2008, HAMOSTASEOLOGIE, V28, pS55
[9]   Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic [J].
Jain, Shilpa ;
Donkin, Jennifer ;
Frey, Mary-Jane ;
Peltier, Skye ;
Gunawardena, Sriya ;
Cooper, David L. .
JOURNAL OF BLOOD MEDICINE, 2018, 9 :211-218
[10]   Prophylaxis of peripartum haemorrhage using recombinant factor Vila (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review [J].
Loddo, Alessandro ;
Cornacchia, Stefania ;
Lo Cane, Fiorenza ;
Barcellona, Doris ;
Marongiu, Francesco ;
Melis, Gian Benedetto ;
Angioni, Stefano ;
Paoletti, Anna Maria ;
Neri, Manuela .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2019, 235 :77-80